Bronchiectasis: a neglected and overlooked lung condition with unrealised commercial potential
We are collaborating with industry experts and Asthma +Lung UK to raise awareness and support the advancement of new innovations and research into bronchiectasis.
Bronchiectasis is the UK’s third most common chronic lung condition affecting 1 in 200 adults, yet remains largely unknown. It is complex, often under-diagnosed and misdiagnosed, and currently has no licensed treatments available.
We are dedicated to advancing medical research focused on the diagnosis and treatment of bronchiectasis. With Asthma + Lung UK, we want to reach both to those studying bronchiectasis and industry players to consider the opportunities available in advancing new innovations.
The commercial potential of bronchiectasis research and development
No treatments currently licensed
There is a significant unmet need that innovative therapies could address
People need a lifetime of treatment
Bronchiectasis is a chronic, long-term condition that typically requires lifelong management and interventions
Increasing prevalence
The number of cases worldwide represents a substantial market opportunity, and this is growing due to demographics and increased confidence in diagnosis
1 in 200
adults in the UK have bronchiectasis
19.9%
global growth rate expected over the next 10 years
Read our Bronchiectasis Industry Factsheet
Opportunities exist for companies with:
- anti-inflammatory knowledge and expertise in drug discovery and development
- anti-infection treatments
- historical experience in COPD, asthma, cystic fibrosis or other chronic respiratory conditions
- diagnostic expertise and capabilities that could be applied to finding better ways to diagnose the condition and monitor responses to treatment
Expert voices and lived experiences
James Chalmers
Chair of Respiratory Research, Asthma + Lung UK
“We urgently need better treatments, that means we need investment into clinical trials and also into translational science in order to understand the disease better, find better treatment targets and help us to develop those new therapies.”
Amelia Shoemark
Professor of Respiratory Research, University of Dundee
“Bronchiectasis is the third most common respiratory condition, and the number of people diagnosed every year is rising. But until relatively recently, very little was understood about bronchitis, what causes it, what causes it to progress, and also what causes flare ups.”
Fiona Mosgrove
GP with a special interest in respiratory medicine
“With the exciting research we have in bronchiectasis driving some incredible new treatments it is more important than ever that we are able to diagnose our patients in a timely fashion so that they can access those treatments.”
Arietta Spinou
Researcher, Kings College London & Respiratory Physiotherapist
“It is really important to work in collaboration and support this type of research because this is what guides our clinical practice and we need to test what are the ideologies and the best treatments in order for us to apply them in real life.”
Steven Tait
Senior Business Manager for Chronic Respiratory Infection, LifeArc
“People with bronchiectasis (BE) live with a significant burden of ill-health that is poorly diagnosed and treated. LifeArc is working with partners to accelerate the development of treatments, and ways to better diagnose BE.”
Gaynor Hardman
Lives with bronchiectasis
“A new treatment for bronchiectasis would be life changing, it would help with feelings of anxiety and stress brought about by not knowing whether you have the right treatment available and whether it is going to work.”
Want to know more?
Get in touch with the team using the form below.
Contact us
In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. If you would like your data to be removed, please email dataprivacy@lifearc.org.
Please see our Privacy Policy in relation to the personal data you submit to us through this page.
